All widely used BRCA1 mutant breast cancer cell lines have deletions in either RB or p16 [35, 36], reflecting the importance of inactivation of the INK4-CDK4/6-RB pathway in the proliferation of BRCA1-deficient tumor cells. This evidence concerns the gene CDK4 and breast carcinoma.